
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biosci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Biosci. Rep</journal-id><journal-id journal-id-type="hwp">ppbioscirep</journal-id><journal-id journal-id-type="publisher-id">BSR</journal-id><journal-title-group><journal-title>Bioscience Reports</journal-title></journal-title-group><issn pub-type="ppub">0144-8463</issn><issn pub-type="epub">1573-4935</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27512093</article-id><article-id pub-id-type="pmc">5041160</article-id><article-id pub-id-type="publisher-id">e00383</article-id><article-id pub-id-type="doi">10.1042/BSR20160038</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Papers</subject></subj-group><subj-group subj-group-type="overline"><subject>Original Paper</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>52</subject><subject>49</subject><subject>10</subject><subject>47</subject></subj-group></article-categories><title-group><article-title>Role of the prostaglandin E<sub>2</sub> receptor agonists in TGF-&#x003b2;1-induced mesangial cell damage</article-title><alt-title alt-title-type="right-running-head">Effect of PGE<sub>2</sub> receptor agonists in MCs damage</alt-title><alt-title alt-title-type="left-running-head">P.-p. Xi and others</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xi</surname><given-names>Pei-pei</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="author-notes" rid="fn1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yu-yin</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="author-notes" rid="fn1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiao-lan</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="corresp" rid="COR1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Ya-ping</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jian-hua</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><aff id="A1"><label>*</label>Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China</aff><aff id="A2"><label>&#x02020;</label>Department of Emergency, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China</aff></contrib-group><author-notes><fn id="fn1" fn-type="other"><label><sup>1</sup></label><p>Joint first authors.</p></fn><corresp id="COR1"><label><sup>2</sup></label>To whom correspondence should be addressed (email <email>chenxl8448@sina.com</email>).</corresp></author-notes><pub-date pub-type="epreprint"><day>10</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>29</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2016</year></pub-date><volume>36</volume><issue>5</issue><issue-id pub-id-type="display">5</issue-id><elocation-id>e00383</elocation-id><history><date date-type="received"><day>12</day><month>2</month><year>2016</year></date><date date-type="rev-recd"><day>18</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 The Author(s)</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution Licence 4.0 (CC BY)</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="bsr036e383.pdf"/><abstract><p>PGE<sub>2</sub> exerts its biological effect through binding to various EP receptors that result inactivation of various signal transduction pathways. It also plays an important role in mice glomerular mesangial cells (MCs) damage induced by transforming growth factor-&#x003b2;1 (TGF-&#x003b2;1); however, the molecular mechanisms remain unknown. In the present study, we tested the efficacy of four selective agonists of PGE<sub>2</sub> receptor, EP<sub>1</sub>A (17-phenyl trinor prostaglandin E<sub>2</sub> ethyl amid), EP<sub>2</sub>A (butaprost), EP<sub>3</sub>A (sulprostone) and EP<sub>4</sub>A (cay10580), on mice MCs. Compared with the cAMP produced by TGF-&#x003b2;1, additional pretreatment of EP<sub>3</sub>A decreased the cAMP level. MCs treated with EP<sub>1</sub>A and EP<sub>3</sub>A augmented PGE<sub>2</sub>, cyclooxygenase-2 (COX-2), membrane-bound PGE synthase 1 (mPGES1), laminin (LN), connective tissue growth factor (CTGF) and cyclin D1 expression stimulated by TGF&#x003b2;1. EP<sub>1</sub>A and EP<sub>3</sub>A increased the number of cells in S+G2/M phase and reduced cells in G0/G1 phase. EP<sub>1</sub> and EP<sub>3</sub> agonists also strengthened TGF&#x003b2;1-induced mitogen-activated protein kinase (p38MAPK) and extracellular-signal-regulated kinase 1/2 (ERK1/2) phosphorylation. Whereas MCs treated with EP<sub>2</sub>A and EP<sub>4</sub>A weakened PGE<sub>2</sub>, COX-2, mPGES1, LN, CTGF and cyclin D1 expression stimulated by TGF&#x003b2;1. EP<sub>2</sub>A and EP<sub>4</sub>A decreased the number of cells in S+G2/M phase and increased cells in G0/G1 phase. EP<sub>2</sub> and EP<sub>4</sub> agonists weakened TGF&#x003b2;1-induced p38MAPK and ERK1/2 phosphorylation. These findings suggest that PGE<sub>2</sub> has an important role in the progression of kidney disease via the EP<sub>1</sub>/EP<sub>3</sub> receptor, whereas EP<sub>2</sub> and EP<sub>4</sub> receptors are equally important in preserving the progression of chronic kidney failure. Thus, agonists of EP<sub>2</sub> and EP<sub>4</sub> receptors may provide a basis for treating kidney damage induced by TGF-&#x003b2;1.</p></abstract><kwd-group kwd-group-type="kwd"><kwd>agonist</kwd><kwd>MAPKs signalling pathway</kwd><kwd>mesangial cells</kwd><kwd>prostaglandin E<sub>2</sub> receptors</kwd><kwd>TGF-&#x003b2;1</kwd></kwd-group><counts><fig-count count="9"/><table-count count="1"/><ref-count count="35"/><page-count count="12"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Renal fibrosis, characterized by glomerulosclerosis and tubulointerstitial fibrosis, is the final common manifestation of a wide variety of chronic kidney diseases (CKD). CKD can be caused by a variety of factors, including diabetes, hypertension, infections, atherosclerosis, renal artery and ureteral obstruction and genetic alterations [<xref rid="B1" ref-type="bibr">1</xref>]. TGF-&#x003b2; has been recognized as an important mediator in the genesis of CKD, which is characterized by the accumulation of extracellular matrix (ECM) components in the glomeruli (glomerular fibrosis, glomerulosclerosis) and the tubular interstitium (tubulointerstitial fibrosis). Extensive studies have demonstrated that TGF-&#x003b2; induces mesangial expansion caused by mesangial cells (MCs) hypertrophy, proliferation (and eventually apoptosis) and ECM synthesis [<xref rid="B2" ref-type="bibr">2</xref>]. Accumulating evidences have suggested that eicosanoids derived from cyclooxygenase-2 (COX-2) and PGE<sub>2</sub> participate in a number of pathological processes in immune-mediated renal diseases [<xref rid="B3" ref-type="bibr">3</xref>]. PGE<sub>2</sub> has been shown to have multiple biological effects in the kidney including the regulation of vascular smooth muscle tonus, glomerular filtration, renin release and tubular salt and water transport. Similarly, in disease states such as diabetic nephropathy, PGE<sub>2</sub> synthesis is elevated [<xref rid="B4" ref-type="bibr">4</xref>]. However, the biologic consequences of increased glomerular PGE<sub>2</sub> synthesis under pathological environment remain poorly understood and worth our further study. Kreisberg found that MCs from diabetic rats and normal MCs cultured under high-glucose conditions produced significantly greater amounts of PGE<sub>2</sub> than control MCs. Increased PGE<sub>2</sub> production occurred concomitant with an increase in MCs proliferation [<xref rid="B5" ref-type="bibr">5</xref>]. Rodr&#x000ed;guez-Barbero et al. [<xref rid="B3" ref-type="bibr">3</xref>] also demonstrated that TGF-&#x003b2;1 induced production of PGE<sub>2</sub> through the activation of MAPK signalling pathway, which was followed by increased proliferation of MCs.</p><p>The pharmacological activity of PGE<sub>2</sub> is carried out via four different cell surface receptor subtypes: EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub> [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref>]. All the four EP receptors have been localized in the kidney. EP<sub>2</sub> and EP<sub>4</sub> receptors couple to Gs, and activation of these receptors results in stimulation of adenylate cyclase, increases intracellular cAMP and activation of protein kinase A (PKA) [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>]. However, EP<sub>2</sub> and EP<sub>4</sub> receptor will play a different role in some physiological or pathophysiological process. Stimulation of the EP<sub>1</sub> receptor results in activation of phosphatidylinositol (PI) hydrolysis and elevation of intracellular Ca<sup>2+</sup> concentration [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. The major signalling pathway described for the EP<sub>3</sub> receptor is mediated by Gi and leads to a reduction in intracellular cAMP levels. But further studies have shown that certain splice variants of EP<sub>3</sub> could activate cAMP production and promote the effect of IP<sub>3</sub> [<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B13" ref-type="bibr">13</xref>]. In order to explore the different roles of the four receptors, we first identified the expression of EP<sub>1</sub>&#x02013;EP<sub>4</sub> by RT-PCR, and then used agonists of EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub> to assess their effects on TGF-&#x003b2;1-induced cell damage and whether the regulation involves cAMP and MAPKs pathways.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Materials</title><p>Murine MCs were kindly provided by donors Fudan University; cAMP and PGE<sub>2</sub> ELISA kits were obtained from R&#x00026;D; TGF-&#x003b2;1 was obtained from Peprotech; 17-phenyl PGE<sub>2</sub> (EP<sub>1</sub>A, EP<sub>1</sub> agonist, prostanoid receptor agonist selectivity: EP<sub>1</sub>&#x0003e;EP<sub>3</sub>), butaprost (EP<sub>2</sub>A, EP<sub>2</sub> agonist), sulprostone (EP<sub>3</sub>A, prostanoid receptor agonist selectivity: EP<sub>3</sub>&#x0003e;EP<sub>1</sub>) and cay10580 (EP<sub>4</sub>A, EP<sub>4</sub> agonist) were obtained from Cayman; Rabbit anti-phospho-p38 MAPK (Thr-180/Tyr-182), phospho-ERK1/2 (Thr-202/Tyr-204), phospho-JNK1/2 (T183/Y185), total JNK, total ERK1/2, total p38, p27kip1, cyclin D1, COX-2 were obtained from Cell Signaling Technology. Mouse anti-CCN2/connective tissue growth factor (CTGF), membrane-bound PGE synthase 1 (mPGES1), laminin (LN) were obtained from Abcam; Dulbecco's modified Eagle's medium, phosphate-buffered saline, trypsin, non-essential amino acids and antibiotics (penicillin/streptomycin) were obtained from Invitrogen; all solutions and instruments for RT-PCR were obtained from Applied Biosystems; 100-mm and 6-well cell culture plates were obtained from Fisher. The experimental protocol was approved by the Experimentation Ethics Committee of the Nantong University for the use of human or animal subjects.</p></sec><sec><title>Cell culture</title><p>Mouse MCs were cultured in Dulbecco's modified Eagle's medium supplemented with 0.1&#x000a0;mM non-essential amino acids, 10% foetal bovine serum (FCS), 100&#x000a0;units/ml penicillin and 0.1&#x000a0;mg/ml streptomycin at 37&#x000b0;C in a humidified incubator containing 5% CO<sub>2</sub>. Cells were grown to 80% confluence and then rendered quiescent 24&#x000a0;h before experiment by the removal of serum and growth factor additives. Specified agonists were next added in serum-free bovine serum albumin medium for 30&#x000a0;min prior to the addition of TGF-&#x003b2;1 (10&#x000a0;ng/ml). Based on our pre-experimental results, the optimal treatment time and most effective concentration of TGF-&#x003b2;1 for MCs was 24&#x000a0;h and 10&#x000a0;ng/ml respectively [<xref rid="B14" ref-type="bibr">14</xref>]. In the experiment, we choose three different concentrations of EP agonists (10, 1, 0.1&#x000a0;&#x003bc;mol/l). And results show that the most effective concentration of the agonists was 1.0&#x000a0;&#x003bc;M. TGF-&#x003b2;1 treatments were generally for 24&#x000a0;h for both RNA analyses and protein analyses.</p></sec><sec><title>RT-PCR for prostaglandin E<sub>2</sub> receptors</title><p>To detect the expression of prostaglandin E<sub>2</sub> receptors in MCs, we performed RT-PCR. Total RNA was extracted from MCs using the TRI Reagent according to the manufacturer's instructions (Molecular Research Center) and was treated with DNase I to remove contaminating DNA. Two micrograms of RNA was reverse transcribed using Omniscript (Qiagen) in a final volume of 20 ul; this reaction mixture was subsequently divided so that EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub> were amplified from the same reverse transcription mixture using 2 ul in the PCR reaction. Primers for EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub> are described in <xref ref-type="table" rid="T1">Table 1</xref>. After an initial activation at 94&#x000b0;C for 90&#x000a0;s, PCR was performed for 35 cycles with the following parameters: denaturation at 94&#x000b0;C for 30&#x000a0;s, annealing at 58&#x000b0;C for EP<sub>1</sub>, EP<sub>3</sub> and EP<sub>4</sub> and at 66&#x000b0;C for EP<sub>2</sub> for 1&#x000a0;min, extension at 72&#x000b0;C for 1&#x000a0;min. A final extension was performed at 72&#x000b0;C for 5&#x000a0;min followed by a 4&#x000b0;C hold. Aliquots of the PCR products were then run on a 2% agarose gel in 1&#x000d7; tris-borate EDTA and visualized by ethidium bromide staining and UV illumination.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><title>Primers used for PCR</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Forward Primer</th><th rowspan="1" colspan="1">Reverse Primer</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">EPI</td><td rowspan="1" colspan="1">GCTGCCTATCTTCTCCATGA</td><td rowspan="1" colspan="1">TCTGCGCTTGGAGTGATAGA</td></tr><tr><td rowspan="1" colspan="1">EP2</td><td rowspan="1" colspan="1">ATACTTAGGCCACCGGTCCT</td><td rowspan="1" colspan="1">TGAAGCGCATCCTCACAACT</td></tr><tr><td rowspan="1" colspan="1">EP3</td><td rowspan="1" colspan="1">GCTGCCTATCTTCTCCATGA</td><td rowspan="1" colspan="1">GTATACAGGCGAAGCACCAG</td></tr><tr><td rowspan="1" colspan="1">EP4</td><td rowspan="1" colspan="1">TAGGTCCTGAACATCTGAGGC</td><td rowspan="1" colspan="1">CTTGCGCGACTTGCACAATA</td></tr><tr><td rowspan="1" colspan="1">COX2</td><td rowspan="1" colspan="1">TGAGTACCGCAAACGCTTCT</td><td rowspan="1" colspan="1">TCTAGTCTGGAGTGGGAGGC</td></tr><tr><td rowspan="1" colspan="1">Mpgesl</td><td rowspan="1" colspan="1">GCCTGGTGATGGAGAGCG</td><td rowspan="1" colspan="1">AGATGGTGGGCCACCTCC</td></tr><tr><td rowspan="1" colspan="1">LN</td><td rowspan="1" colspan="1">CTCGTCCCGGTTTCTAAAGG</td><td rowspan="1" colspan="1">TTTCCTGCCCTTCTCTCTCA</td></tr><tr><td rowspan="1" colspan="1">CTGF</td><td rowspan="1" colspan="1">CAAAGCAGCTGCAAATACCA</td><td rowspan="1" colspan="1">GGCCAAATGTGTCTTCCAGT</td></tr><tr><td rowspan="1" colspan="1">P27</td><td rowspan="1" colspan="1">CAGCTTGCCCGAGTTCTACT</td><td rowspan="1" colspan="1">TCTGACGAGTCAGGCATTTG</td></tr><tr><td rowspan="1" colspan="1">Cyclin Dl</td><td rowspan="1" colspan="1">GCGTACCCTGACACCAATCT</td><td rowspan="1" colspan="1">CTCTTCGCACTTCTGCTCCT</td></tr><tr><td rowspan="1" colspan="1">GAPDH</td><td rowspan="1" colspan="1">AGAAGGCTGGGGCTCATTTG</td><td rowspan="1" colspan="1">AGGGGCCATCCACAGTCTTC</td></tr></tbody></table></table-wrap></sec><sec><title>Quantitative PCR analysis</title><p>Total RNA of MCs was isolated with the RNeasy Plus Mini kit (Qiagen) according to the manufacturer's instructions. Afterward, cDNA was synthesized by iScript reverse transcription (Bio-Rad Laboratories), which was then subjected to SYBR Green-based qRT-PCR using the SYBR Green JumpStart kit (Sigma&#x02013;Aldrich). PCR reactions were performed and analysed on a Bio-Rad Mini-Opticon detection system, and differences in RNA concentration were controlled by normalizing individual gene signals to those of their corresponding GAPDH reactions. The oligonucleotide primers used are listed in <xref ref-type="table" rid="T1">Table 1</xref>.</p></sec><sec><title>Western blotting</title><p>To examine the expression of cell cycle regulatory molecules we used a Cell Cycle Sampler kit (Cell Signaling Technology) that contains antibodies to all of the molecules (COX-2, mPGES1, P27, cyclin D1, CTGF, LN, P-JNK/p38/ERK and T-JNK/p38/ERK) used in the present study. Proteins were separated by 10% polyacrylamide gel electrophoresis and then transferred on to PVDF membranes (Millipore) at 350 mA for 2&#x000a0;h, which was later soaked for 2&#x000a0;h on a blocking solution (Tris-buffered saline containing 5% nonfat dry milk and 0.01% vol/vol Tween-20). Membranes were incubated overnight at 4&#x000b0;C with rabbit monoclonal primary antibody. After washing with TBS-Tween, membranes were incubated with a horseradish peroxidase-conjugated secondary antibody for 1&#x000a0;h at room temperature. After further washing they were developed using an enhanced chemiluminescent detection method (Amersham Life Science). The membranes were then stripped and re-probed for actin as a loading control.</p></sec><sec><title>Measurement of PGE<sub>2</sub> in culture medium and intracellular cAMP in MCs</title><p>ELISA kits for the detection of cAMP and PGE<sub>2</sub> were obtained from Sigma and experiments followed the manufacturer's suggested guidelines. Briefly, MCs were cultured in 6-well plates and grown until confluent and subsequently serum deprived for a minimum of 24&#x000a0;h. Cells were then challenged with specified agonist for 30&#x000a0;min prior to the addition of TGF-&#x003b2;1 (10&#x000a0;ng/ml) for 24&#x000a0;h. Culture lysates were then harvested and maintained on ice until the assay was conducted. PGE<sub>2</sub> and cAMP concentration in the culture medium was measured. Absorbance was measured at 550&#x000a0;nm and data were analysed via interpolation with standards using semilogarithmic paper. A minimum of <italic>n</italic>=3 for each experimental condition was performed.</p></sec><sec><title>Cell cycle analysis</title><p>Cells were trypsinized, suspended and washed with PBS. Cell pellets were fixed in 70% ethanol 2&#x000a0;h and then washed with PBS three times. The single-cell suspension was adjusted to 10<sup>7</sup> cells/ml and stained by propidium iodide staining solution at 4&#x000b0;C for 30&#x000a0;min in the dark. Flow cytometric analysis was performed at a flow rate of 100 events/s using a dual-laser flow cytometer. A total of 10000 events were counted. Cell debris and clumps were excluded from the analysis by gating single cells in the forward and side light scatters. Propidium iodide was excited using the 488-nm UV line of the argon laser. Data were analysed with FCS software (<italic>De Novo</italic> Software).</p></sec><sec><title>Statistical analysis</title><p>All experiments were performed in triplicate and the results were expressed as means &#x000b1; S.E.M. All data were analysed with SPSS 19.0 statistical software using a one-way ANOVA. Two-tailed <italic>P</italic> values of &#x0003c;0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Expression of EP receptors in MCs</title><p>The mRNA expression of the four EP receptors in MCs was analysed by RT-PCR. The result (<xref ref-type="fig" rid="F1">Figure 1</xref>) shows all four PGE<sub>2</sub> receptors (EP receptors) were expressed in mouse MCs.</p><fig id="F1" position="float"><label>Figure 1</label><caption><title>Agarose gel electrophoresis showing RT-PCR products of EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub> receptor expression in cultured mice MCs</title></caption><graphic xlink:href="bsr036e383fig1"/></fig></sec><sec><title>Effects of selective EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists on intracellular cAMP levels in mouse MC stimulated with TGF-&#x003b2;1</title><p>MCs were pre-incubated with EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists for 30&#x000a0;min and exposed to TGF-&#x003b2;1 for 10&#x000a0;min. Then, cAMP production was determined by ELISA. Data demonstrated that TGF-&#x003b2;1 caused a slight increase in cAMP in mouse MCs. EP<sub>1</sub> agonist treatment showed no significant effects on cAMP level compared with TGF-&#x003b2;1 treated MCs. EP<sub>3</sub>A (1&#x000a0;&#x003bc;M) inhibited TGF-&#x003b2;1-induced cAMP production. In contrast, MCs treated with EP<sub>2</sub>A or EP<sub>4</sub>A increased cAMP levels compared with the control cells (<xref ref-type="fig" rid="F2">Figure 2</xref>). The differences were significant.</p><fig id="F2" position="float"><label>Figure 2</label><caption><title>MCs were pre-incubated for 30&#x000a0;min with EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists (1.0&#x000a0;&#x003bc;M) and exposed to TGF-&#x003b2;1 (10&#x000a0;ng/ml) for 10 min</title><p>Cyclic AMP levels were assessed using cAMP ELISA as described under &#x02018;Experimental Procedures&#x02019;. Each experimental condition was performed multiple times (<italic>n</italic>=3). Data are expressed as the S.E.M., *<italic>P</italic>&#x0003c;0.05 compared with Control group, <sup>#</sup><italic>P</italic>&#x0003c;0.05 compared with 10&#x000a0;ng/ml TGF-&#x003b2;1 group.</p></caption><graphic xlink:href="bsr036e383fig2"/></fig></sec><sec><title>Role of EP receptors in the regulation of TGF-&#x003b2;1-induced expression of COX-2 and mPGES1 and secretion of PGE2&#x000a0;in mouse MC</title><p>To determine the effect of EP receptors on the prostanoid synthetic pathway, we used real-time quantitative RT-PCR and western blotting to compare mRNA and protein abundance of COX-2 and mPGES1&#x000a0;in each group. MCs were pre-incubated with EP<sub>1-4</sub> receptor agonists for 30&#x000a0;min and exposed to TGF-&#x003b2;1 for 24&#x000a0;h. As shown in <xref ref-type="fig" rid="F3">Figure 3</xref>, TGF-&#x003b2;1 induced the expression of COX-2 and mPGES1 mRNA as well as protein. Compared with TGF-&#x003b2;1 treated MCs, the expression of COX-2 and mPGES1&#x000a0;in MCs treated with EP<sub>2</sub>A or EP<sub>4</sub>A was significantly suppressed. In contrast, there was a significant elevation in COX-2 and mPGES1 expression in MCs treated with EP1 or EP<sub>3</sub> receptor agonists.</p><fig id="F3" position="float"><label>Figure 3</label><caption><title>MCs cultures were pretreated for 30&#x000a0;min with EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists (1.0&#x000a0;&#x003bc;M), respectively, prior to the addition of 10&#x000a0;ng/ml TGF&#x003b2;1</title><p>Cultures were incubated for an additional 24&#x000a0;h prior to harvest of total protein and mRNA for qPCR and Western blot. Western blot and RT-PCR analysis were used to determine the expressions of COX-2, mPGES1. (<bold>A</bold>) RT-PCR; (<bold>B</bold>) Western blot. Each experimental condition was performed multiple times (<italic>n</italic>=3). Data are expressed as the S.E.M., *<italic>P</italic>&#x0003c;0.05 compared with Control group, <sup>#</sup><italic>P</italic>&#x0003c;0.05 compared with 10&#x000a0;ng/ml TGF-&#x003b2;1 group.</p></caption><graphic xlink:href="bsr036e383fig3"/></fig><p>We next assessed whether the change in COX-2 and mPGES1 expression has a functional consequence such as an adjustment in prostanoids production. We then examined the production of PGE<sub>2</sub> by ELISA in culture supernatants. Our results suggested that PGE<sub>2</sub> production was consistent with the increase in COX-2 and mPGES1 expression (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><title>Production of PGE<sub>2</sub> in culture supernatants was determined by ELISA</title><p>MCs cultures were pretreated for 30&#x000a0;min with EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists (1.0&#x000a0;&#x003bc;M), respectively, prior to the addition of 10&#x000a0;ng/ml TGF&#x003b2;1 for an additional 24&#x000a0;h. Each experimental condition was performed multiple times (<italic>n</italic>=3). Data are expressed as the S.E.M., *<italic>P</italic>&#x0003c;0.05 compared with Control group, <sup>#</sup><italic>P</italic>&#x0003c;0.05 compared with 10&#x000a0;ng/ml TGF-&#x003b2;1 group.</p></caption><graphic xlink:href="bsr036e383fig4"/></fig></sec><sec><title>Effects of selective EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists on TGF-&#x003b2;1-induced expression of mRNA and protein of LN and CTGF</title><p>Published reports have shown that TGF-&#x003b2;1 also plays a major role in glomerular ECM accumulation in several glomerular diseases [<xref rid="B15" ref-type="bibr">15</xref>]. Because PGE<sub>2</sub> levels are increased in MCs, we suspected that accumulation of ECM induced by TGF-&#x003b2;1 may be due to the increased PGE<sub>2</sub> levels. We therefore investigated the role of EP receptors in the regulation of accumulation of ECM. MCs were pre-incubated with EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists for 30&#x000a0;min and exposed to TGF-&#x003b2;1 for 24&#x000a0;h. As shown in <xref ref-type="fig" rid="F5">Figure 5</xref>, TGF-&#x003b2;1-induced expression of LN and CTGF was inhibited by EP<sub>2</sub>A and EP<sub>4</sub>A, but enhanced by EP<sub>1</sub> or EP<sub>3</sub> receptor agonists in MCs.</p><fig id="F5" position="float"><label>Figure 5</label><caption><title>MCs cultures were pretreated for 30&#x000a0;min with EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists (1.0&#x000a0;&#x003bc;M), respectively, prior to the addition of 10&#x000a0;ng/ml TGF-&#x003b2;1 for an additional 24 h</title><p>Total protein and mRNA were harvested for RT-PCR and Western blot. Western blot and RT-PCR analysis were used to determine the expressions of LN and CTGF. (<bold>A</bold>) RT-PCR; (<bold>B</bold>) Western blot. Each experimental condition was performed multiple times (<italic>n</italic>=3). Data are expressed as the S.E.M., *<italic>P</italic>&#x0003c;0.05 compared with Control group, <sup>#</sup><italic>P</italic>&#x0003c;0.05 compared with 10&#x000a0;ng/ml TGF-&#x003b2;1 group.</p></caption><graphic xlink:href="bsr036e383fig5"/></fig></sec><sec><title>Effect of four selective EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists on MC cycle and TGF-&#x003b2;1-induced expression of p27kip1 and cyclin D1</title><p><xref ref-type="fig" rid="F6">Figure 6</xref> shows the effects of TGF-&#x003b2;1 and four EP agonists on the cell cycle phase distribution of MCs. The results showed that treatment with TGF-&#x003b2;1 (10&#x000a0;ng/ml) for 24&#x000a0;h resulted in cell accumulation in S+G2/M phase and reduction in G0/G1 phase, compared with the control cells. Pre-treatment with EP<sub>2</sub>A or EP<sub>4</sub>A (1.0&#x000a0;&#x003bc;M), most cells were arrested in G0/G1 phase, whereas pre-treatment with EP<sub>1</sub>A or EP<sub>3</sub>A (1.0&#x000a0;&#x003bc;M) were manifesting just the opposite way. The results of western blotting showed that TGF-&#x003b2;1 decreased the expression of p27kip1 (<italic>P</italic>&#x0003c;0.05). The p27kip1 protein level increased in MCs after EP<sub>2</sub>A or EP<sub>4</sub>A treatment, whereas the protein level decreased in EP<sub>1</sub>A or EP<sub>3</sub>A treated MCs (<italic>P</italic>&#x0003c;0.05). And the results of western blotting showed that TGF-&#x003b2;1 increased the expression of cyclin D1 (<italic>P</italic>&#x0003c;0.05). The expression levels of cyclin D1 were down-regulated in MCs treated with EP<sub>2</sub>A or EP<sub>4</sub>A, whereas the expression of cyclin D1 was up-regulated in MCs treated with EP1A or EP<sub>3</sub>A (<italic>P</italic>&#x0003c;0.05) (<xref ref-type="fig" rid="F7">Figure 7</xref>).</p><fig id="F6" position="float"><label>Figure 6</label><caption><title>Cell cycle analysis of MCs assessed by fluorescence-activated cell-sorting analysis</title><p>After pre-incubation in DMEM containing 0.5% FCS for 24&#x000a0;h, growth-arrested cells were pre-treated with or without EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists (1.0&#x000a0;&#x003bc;M) and the co-incubation was continued for 24&#x000a0;h after the addition of TGF-&#x003b2;1 (10&#x000a0;ng/ml) in DMEM containing 0.5% FCS. Cell cycle analysis assessed by the incorporation of propidium iodide into DNA by fluorescence-activated cell-sorting analysis using a dual laser flow cytometer. &#x02460; Cells were treated with 0.5% FCS alone. &#x02461; Cells were treated with TGF-&#x003b2;1 alone for 24&#x000a0;h. &#x02462; Cells were treated with TGF-&#x003b2;1 (10&#x000a0;ng/ml) for 24&#x000a0;h with pre-incubation of 17-phenyl PGE<sub>2</sub>(1.0&#x000a0;&#x003bc;M) for 30&#x000a0;min. &#x02463; With pre-incubation of butaprost(1.0&#x000a0;&#x003bc;M) for 30&#x000a0;min. &#x02464; With pre-incubation of sulprostone (1.0&#x000a0;&#x003bc;M) for 30&#x000a0;min. &#x02465; With pre-incubation of cay10580 (1.0&#x000a0;&#x003bc;M) for 30&#x000a0;min. Data are S.E.M. of three independent experiments.</p></caption><graphic xlink:href="bsr036e383fig6"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title>Western blot and RT-PCR analysis of p27kip1 and cyclin D1</title><p>Cultured and serum-deprived cells were treated with TGF-&#x003b2;1 (10&#x000a0;ng/ml) in DMEM containing 0.5% FCS for 24&#x000a0;h and pre-treatment of EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists (1.0&#x000a0;&#x003bc;M) for 30&#x000a0;min. The expressions of p27kip1 and cyclin D1 were detected with Western blot and RT-PCR. Actin served as a loading control. (<bold>A</bold>) RT-PCR; (<bold>B</bold>) Western blot. Each experimental condition was performed multiple times (<italic>n</italic>=3). Data are expressed as the S.E.M., *<italic>P</italic>&#x0003c;0.05 compared with Control group, <sup>#</sup><italic>P</italic>&#x0003c;0.05 compared with 10&#x000a0;ng/ml TGF-&#x003b2;1 group.</p></caption><graphic xlink:href="bsr036e383fig7"/></fig></sec><sec><title>Multiple MAPK routes participate in PGE<sub>2</sub>-induced proliferation and extracellular matrix synthesis in mouse MC stimulated with TGF-&#x003b2;1</title><p>Western blot analysis demonstrated that TGF-&#x003b2;1 significantly increased the level of the phosphorylated forms of ERK1/2 and p38 but not JNK1/2&#x000a0;in MCs and reached a maximum after 10&#x000a0;min of treatment of TGF-&#x003b2;1 and then decreased gradually. Total ERK1/2 remained constant throughout the duration of the experiment (<xref ref-type="fig" rid="F8">Figure 8</xref>). To determine which receptor is involved in TGF-&#x003b2;1-induced ERK1/2 and p38 phosphorylation in MCs, cells were pre-treated with the EP<sub>1</sub>&#x02013;EP<sub>4</sub> receptor agonists and then treated with TGF-&#x003b2;1 for 10&#x000a0;min. EP<sub>2</sub> and EP<sub>4</sub> agonist considerably attenuated TGF-&#x003b2;1-induced ERK1/2, p38 phosphorylation, whereas EP<sub>1</sub> and EP<sub>3</sub> agonists increased their phosphorylation (<xref ref-type="fig" rid="F9">Figure 9</xref>).</p><fig id="F8" position="float"><label>Figure 8</label><caption><title>MCs were serum-starved for 24&#x000a0;h and then stimulated with TGF-&#x003b2;1 (10&#x000a0;ng/ml) for the indicated time periods</title><p>Total protein extracts were analysed by Western blotting using specific antibodies for total and phosphorylated ERK1/2, p38 MAPK, JNK (*<italic>P</italic>&#x0003c;0.05 compared with 0&#x000a0;h). P-JNK/p38/ERK: phosphorylated JNK, phosphorylated p38, phosphorylated ERK. T-JNK/p38/ERK: Total JNK, Total p38, Total ERK.</p></caption><graphic xlink:href="bsr036e383fig8"/></fig><fig id="F9" position="float"><label>Figure 9</label><caption><title>MCs were serum-starved for 24&#x000a0;h and pretreated with 17-phenyl trinor PGE<sub>2</sub> (1.0&#x000a0;&#x003bc;M), butaprost (1.0&#x000a0;&#x003bc;M), sulprostone (1.0&#x000a0;&#x003bc;M) and cay10580 (1.0&#x000a0;&#x003bc;M) for 30&#x000a0;min before stimulation with TGF-&#x003b2;1 (10&#x000a0;ng/ml) for 10 min</title><p>Total protein extracts were analysed by Western blotting using specific antibodies for total and phosphorylated ERK1/2, p38 MAPK, phosphorylated ERK1/2, p38 MAPK protein expression levels were analysed by Western blotting. Data are expressed as the S.E.M. (*<italic>P</italic>&#x0003c;0.05 compared with Control group, #<italic>P</italic>&#x0003c;0.05 compared with 10&#x000a0;ng/ml TGF-&#x003b2;1 group).</p></caption><graphic xlink:href="bsr036e383fig9"/></fig></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>PGE<sub>2</sub>, a major PG in the kidney, plays an important role in renal physiology, including the regulation of vascular smooth muscle tonus, glomerular filtration, renin release and tubular salt and water transport [<xref rid="B4" ref-type="bibr">4</xref>]. The large variety of biological functions governed by prostaglandin E2 is mediated by signalling through four distinct E-type prostanoid receptors [<xref rid="B16" ref-type="bibr">16</xref>]. Although the regulation mechanism of PGE<sub>2</sub> on salt and water metabolism under physiological conditions are understood, our understanding of how PGE<sub>2</sub> influence&#x000a0;Na or sodium homoeostasis and blood pressure regulation under pathological conditions is in its infancy [<xref rid="B17" ref-type="bibr">17</xref>]. Makino et al. [<xref rid="B18" ref-type="bibr">18</xref>] has shown that an EP<sub>1</sub> antagonist, and a nonselective PG synthase inhibitor, markedly attenuate mesangial expansion, inhibits glomerular hypertrophy and proteinuria of diabetic nephropathy in rats. Black et al. [<xref rid="B19" ref-type="bibr">19</xref>] found that stimulation of the EP<sub>3</sub> receptor with sulprostone resulted in a robust increase in TGF-&#x003b2;1-stimulated CTGF levels in human renal MCs. We speculate that the COX-2&#x02013;PGE<sub>2</sub>&#x02013;EP system might play an important role in the renal fibrosis process.</p><p>The cDNA for these receptors have been cloned, their signal transduction mechanisms determined, and their intrarenal distribution mapped. Four distinct EP receptors are highly expressed in specific regions of the kidney [<xref rid="B4" ref-type="bibr">4</xref>]. In the present paper, EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub> receptors are expressed in the mouse MCs by RT-PCR, although the expression of EP<sub>4</sub> and EP<sub>2</sub> are relatively lower than EP<sub>3</sub> and EP<sub>1</sub>.</p><p>TGF-&#x003b2; is a cytokine known to participate in several processes related to the development of CKD [<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>]. TGF-&#x003b2; is known to induce the expression of COX-2, mPGES1 and PGE<sub>2</sub> in MCs [<xref rid="B14" ref-type="bibr">14</xref>]. The COX-2 inhibitor etodolac significantly reduces TGF-&#x003b2;, resulting in decreased tubular damage and interstitial fibrosis [<xref rid="B22" ref-type="bibr">22</xref>]. What are the four EP receptors' role in the process of renal tubular damage and interstitial fibrosis? We designed studies to determine whether TGF-&#x003b2;1-induced expression of COX-2, mPGES1 and PGE<sub>2</sub> in MCs is affected by four EP receptor agonists. We demonstrate that 17-phenyl PGE<sub>2</sub>(EP<sub>1</sub>A)and sulprostone(EP<sub>3</sub>A) increased the expression of COX-2, mPGES1 and PGE<sub>2</sub> whereas butaprost(EP<sub>2</sub>A)and cay10580 (EP<sub>4</sub>A) decreased their expression. LNs are major proteins in the basal lamina. They are an important and biologically active part of the basal lamina, influencing cell differentiation and migration. CTGF is an established effector of TGF-&#x003b2;1 driven responses in diabetic nephropathy. We next obtained that TGF-&#x003b2;1 stimulated LN and CTGF expression in MCs. Activation of EP<sub>1</sub> and EP<sub>3</sub> by 17-phenyl PGE<sub>2</sub> and Sulprostone notably increased the TGF-&#x003b2;1-induced LN and CTGF protein expression in MCs, whereas EP<sub>2</sub>A and EP<sub>4</sub>A inhibited their expression. We demonstrate that EP<sub>1</sub>A and EP<sub>3</sub>A up-regulate LN and CTGF expression in MCs through the activation of COX-2-PGE<sub>2</sub>, which lead to MCs damage. EP<sub>2</sub> and EP<sub>4</sub> agonists elicit opposite responses. All these data suggest that PGE<sub>2</sub> via EP<sub>2</sub> and EP<sub>4</sub> may slow the progression of renal fibrosis whereas EP<sub>1</sub> and EP<sub>3</sub> may promote the process of renal damage.</p><p>Among many factors that regulate matrix deposition in different ways, TGF-&#x003b2;1 is the most potent inducer that is capable of initiating and completing the entire matrix deposition&#x000a0;course. However, TGF-&#x003b2;1 may also have other important functions in the glomerulus, including the regulation of MCs proliferation [<xref rid="B23" ref-type="bibr">23</xref>]. Cell cycle progression is driven by the coordinated regulation of the activities of cyclin, cyclin-dependent kinases (Cdks) and Cdk-inhibitor (CKI) [<xref rid="B24" ref-type="bibr">24</xref>]. CKIs are regulated by intracellular signalling pathways mediated by extracellular growth factors [<xref rid="B25" ref-type="bibr">25</xref>]. p27Kip1 blocks the catalytic activity of cyclin/Cdk complexes, inducing cell cycle arrest in mid-G1 phase [<xref rid="B26" ref-type="bibr">26</xref>]. Cyclin D1 involved in the regulation of cell cycle from G1 to S phase. In our study, TGF-&#x003b2;1 increased the proportion of MCs arrested in G2/S phase and the proliferation of cyclin D1, whereas down-regulated the expression of P27 protein and mRNA. EP<sub>1</sub>A and EP<sub>3</sub>A promoted TGF-&#x003b2;1-induced MCs proliferation, whereas EP<sub>2</sub>A and EP<sub>4</sub>A alleviated such effects of TGF-&#x003b2;1 on MCs. Thus, the above results suggest that increased production of PGE<sub>2</sub> induced activation of EP<sub>1</sub> and EP<sub>3</sub>, which then led to TGF-&#x003b2;1-induced changes of cell proliferation and cell cycle. Whereas EP<sub>2</sub> and EP<sub>4</sub> are important in preserving the cell proliferation.</p><p>However, what are the molecular mechanisms underlying the effects of EP<sub>1</sub>&#x02013;EP<sub>4</sub> on TGF-&#x003b2;1-induced MCs damage? MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. At least three MAPK families have been characterized: extracellular signal-regulated kinase (ERK), Jun kinase (JNK/SAPK) and p38 MAPK [<xref rid="B27" ref-type="bibr">27</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>]. Specific activation of MAPK pathways may mediate TGF-&#x003b2;1-induced cell or tissue effects. Therefore, our study mainly focused on the interaction between cAMP and MAPK signalling pathways. We found that ERK and p38 were activated obviously after stimulation of MCs with TGF-&#x003b2;1 for 10&#x000a0;min whereas this treatment showed no significant effects on JNK levels. EP<sub>1</sub> agonist treatment showed no significant effects on cAMP levels, but the expression of p-p38 and p-ERK was increased. Furthermore, cAMP production in response to TGF-&#x003b2;1 was markedly reduced in MCs treated with EP<sub>3</sub> agonist whereas ERK and p38 phosphorylation was increased. The level of TGF-&#x003b2;1-dependent cAMP production was increased with EP<sub>2</sub> or EP<sub>4</sub> agonist treatment whereas ERK and p38 phosphorylation was decreased. Taken together, these results demonstrate that EP<sub>1</sub> agonist can activate p38MAPK and ERK phosphorylation by regulating gated calcium channel through G protein. EP<sub>3</sub> agonist blocked cAMP production, at least in part, by inhibiting adenylate cyclase activity through inhibitory G protein receptor and resulted in activation of p38MAPK and ERK phosphorylation. Such reactions are critical mediators of renal injury by promoting MCs proliferation and ECM fibrosis. By contrast, EP<sub>2</sub> and EP<sub>4</sub> agonists showed the opposite effects on TGF-&#x003b2;1-induced MCs injury. It is indicating that inhibition of p38MAPK and ERK phosphorylation is dependent on cAMP production [<xref rid="B30" ref-type="bibr">30</xref>&#x02013;<xref rid="B32" ref-type="bibr">32</xref>].</p><p>Although 17-phenyl PGE<sub>2</sub> and sulprostone can activate EP<sub>1</sub> and EP<sub>3</sub> receptors simultaneously, their G protein-coupled receptors and specific downstream effectors are different. But both of EP<sub>1</sub> and EP<sub>3</sub> can activate the MAPKS signalling pathway and induce p38MAPK and ERK phosphorylation. Our results provide evidence that EP<sub>1</sub> and EP<sub>3</sub> receptors may play an important role in TGF-&#x003b2;1-induced MCs injury. Furthermore, we showed that when MCs were treated with butaprost or cay10580, the levels of cell fibrosis markers were significantly decreased, suggesting that EP<sub>2</sub> and EP<sub>4</sub> agonists can prevent the development of TGF-&#x003b2;1-induced MCs injury, these data were in agreement with those of Zahner et al. [<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>]. However, Mohamed et al. [<xref rid="B35" ref-type="bibr">35</xref>] found that EP<sub>4</sub> agonist through IL-6 induced glomerulosclerosis and interstitial fibrosis of kidneys in an animal model of type&#x000a0;1 diabetes. Whether the contradiction between the two results was ultimately due to different agonist concentration or differences in actual action time of EP<sub>4</sub> or tissue difference or any other reasons should be further studied. Furthermore, it may be due to the dual role of PGE<sub>2</sub>.</p><p>In conclusion, our results demonstrate that in cultures of MCs, TGF-&#x003b2;1 induces cell proliferation and the production of ECM, increase the expression of COX-2, mPGES1 and PGE<sub>2</sub>. EP<sub>1</sub> and EP<sub>3</sub> agonists both aggravated TGF-&#x003b2;1-mediated renal injury by promoting the activation of p38MAPK and ERK phosphorylation. In contrast, EP<sub>2</sub> and EP<sub>4</sub> agonists inhibited TGF-&#x003b2;1-induced cell proliferation by inhibiting downstream targets of kinase cascade, such as cell cyclin and CTGF, through inhibition of MAPKs signalling pathway. These results may open up specific strategies for the treatment of renal glomerular inflammatory diseases that specifically target the pathways involved in EP receptor activation.</p></sec></body><back><sec><title>AUTHOR CONTRIBUTION</title><p>Xiao-lan Chen conceived and designed the research; Pei-pei Xi drafted the manuscript. Yu-yin Xu, Xiao-lan Chen, Ya-ping Fan and Jian-hua Wu analysed data; Pei-pei Xi interpreted results of experiments; Pei-pei Xi and Yu-yin Xu prepared figures; Xiao-lan Chen edited and revised the manuscript and approved the final version of manuscript; Pei-pei Xi performed experiments. All authors read and approved the final manuscript.</p></sec><sec><title>FUNDING</title><p>This work was supported by the <funding-source id="gs1">National Natural Science Foundation of China</funding-source> [grant number <award-id rid="gs1">81170656</award-id>]; the <funding-source id="gs2">Jiangsu Basic Research Program</funding-source> [grant number <award-id rid="gs2">BK2008185</award-id>]; and the <funding-source id="gs3">Science Foundation of Nantong City, Jiangsu province, China</funding-source> [grant number <award-id rid="gs3">HS2011021</award-id>].</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="uid1">Cdk</term><def><p>cyclin-dependent kinase</p></def></def-item><def-item><term id="uid2">CKD</term><def><p>chronic kidney diseases</p></def></def-item><def-item><term id="uid3">CKI</term><def><p>CDK-inhibitor</p></def></def-item><def-item><term id="uid4">COX-2</term><def><p>cyclooxygenase-2</p></def></def-item><def-item><term id="uid5">CTGF</term><def><p>connective tissue growth factor</p></def></def-item><def-item><term id="uid6">ECM</term><def><p>extracellular matrix</p></def></def-item><def-item><term id="uid7">ERK1/2</term><def><p>extracellular-signal-regulated kinase 1/2</p></def></def-item><def-item><term id="uid8">FCS</term><def><p>foetal calf serum</p></def></def-item><def-item><term id="uid9">LN</term><def><p>laminin</p></def></def-item><def-item><term id="uid10">MC</term><def><p>mesangial cell</p></def></def-item><def-item><term id="uid11">mPGES1</term><def><p>membrane-bound PGE synthase 1</p></def></def-item><def-item><term id="uid12">PI</term><def><p>phosphatidylinositol</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Renal fibrosis: new insights into the pathogenesis and therapeutics</article-title><source>Kidney Int.</source><year>2006</year><volume>69</volume><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000054</pub-id><pub-id pub-id-type="pmid">16408108</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Hern&#x000e1;ndez</surname><given-names>F.J.</given-names></name><name><surname>L&#x000f3;pez-Novoa</surname><given-names>J.M.</given-names></name></person-group><article-title>Role of TGF-&#x003b2; in chronic kidney disease: an integration of tubular, glomerular and vascular effects</article-title><source>Cell Tissue Res.</source><year>2012</year><volume>347</volume><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1007/s00441-011-1275-6</pub-id><pub-id pub-id-type="pmid">22105921</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Barbero</surname><given-names>A.</given-names></name><name><surname>Dorado</surname><given-names>F.</given-names></name><name><surname>Velasco</surname><given-names>S.</given-names></name><name><surname>Pandiella</surname><given-names>A.</given-names></name><name><surname>Banas</surname><given-names>B.</given-names></name><name><surname>L&#x000f3;pez-Novoa</surname><given-names>J.M.</given-names></name></person-group><article-title>TGF-beta1 induces COX2 expression and PGE<sub>2</sub> synthesis through MAPK and PI3K pathways in human mesangial cells</article-title><source>Kidney Int.</source><year>2006</year><volume>70</volume><fpage>901</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5001626</pub-id><pub-id pub-id-type="pmid">16820791</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breyer</surname><given-names>M.D.</given-names></name><name><surname>Jacobson</surname><given-names>H.R.</given-names></name><name><surname>Breyer</surname><given-names>R.M.</given-names></name></person-group><article-title>Functional and molecular aspects of renal prostaglandin receptors</article-title><source>J. Am. Soc. Nephrol.</source><year>1996</year><volume>7</volume><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">8808104</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreisberg</surname><given-names>J.I.</given-names></name><name><surname>Patel</surname><given-names>P.Y.</given-names></name></person-group><article-title>The effects of insulin, glucose and diabetes on prostaglandin production by rat kidney glomeruli and cultured glomerular mesangial cells</article-title><source>Prostaglandins Leukot. Med.</source><year>1983</year><volume>11</volume><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/0262-1746(83)90097-5</pub-id><pub-id pub-id-type="pmid">6353425</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiraishi</surname><given-names>N.</given-names></name><name><surname>Nomura</surname><given-names>T.</given-names></name><name><surname>Tanizaki</surname><given-names>H.</given-names></name><name><surname>Nakajima</surname><given-names>S.</given-names></name><name><surname>Narumiya</surname><given-names>S.</given-names></name><name><surname>Miyachi</surname><given-names>Y.</given-names></name><name><surname>Tokura</surname><given-names>Y.</given-names></name><name><surname>Kabashima</surname><given-names>K.</given-names></name></person-group><article-title>Prostaglandin E2-EP<sub>3</sub> axis in fine-tuning excessive skin inflammation by restricting dendritic cell functions</article-title><source>PLoS One</source><year>2013</year><volume>29</volume><fpage>e69599</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0069599</pub-id><pub-id pub-id-type="pmid">23922752</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonova</surname><given-names>M.</given-names></name></person-group><article-title>Prostaglandins and prostaglandin receptor antagonism in migraine</article-title><source>Dan. Med. J.</source><year>2013</year><volume>60</volume><fpage>B4635</fpage><pub-id pub-id-type="pmid">23673269</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>C.M.</given-names></name><name><surname>Breyer</surname><given-names>M.D.</given-names></name></person-group><article-title>Physiological regulation of prostaglandins in the kidney</article-title><source>Annu. Rev. Physiol.</source><year>2008</year><volume>70</volume><fpage>357</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.70.113006.100614</pub-id><pub-id pub-id-type="pmid">17988207</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>Y.</given-names></name><name><surname>Narumiya</surname><given-names>S.</given-names></name></person-group><article-title>Prostaglandin E receptors</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>11613</fpage><lpage>11617</lpage><pub-id pub-id-type="doi">10.1074/jbc.R600038200</pub-id><pub-id pub-id-type="pmid">17329241</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breyer</surname><given-names>M.D.</given-names></name><name><surname>Breyer</surname><given-names>R.M.</given-names></name></person-group><article-title>G protein-coupled prostanoid receptors and the kidney</article-title><source>Annu. Rev. Physiol.</source><year>2001</year><volume>63</volume><fpage>579</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.63.1.579</pub-id><pub-id pub-id-type="pmid">11181968</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salinthone</surname><given-names>S.</given-names></name><name><surname>Schillace</surname><given-names>R.V.</given-names></name><name><surname>Tsang</surname><given-names>C.</given-names></name><name><surname>Regan</surname><given-names>J.W.</given-names></name><name><surname>Bourdette</surname><given-names>D.N.</given-names></name><name><surname>Carr</surname><given-names>D.W.</given-names></name></person-group><article-title>Lipoic acid stimulates cAMP production via G protein-coupled receptor-dependent and -independent mechanisms</article-title><source>J. Nutr. Biochem.</source><year>2011</year><volume>22</volume><fpage>681</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2010.05.008</pub-id><pub-id pub-id-type="pmid">21036588</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Dingledine</surname><given-names>R.</given-names></name></person-group><article-title>EP<sub>2</sub> receptor signaling pathways regulate classical activation of microglia</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>9293</fpage><lpage>9302</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.455816</pub-id><pub-id pub-id-type="pmid">23404506</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B.</given-names></name><name><surname>Tsai</surname><given-names>P.</given-names></name><name><surname>Schrier</surname><given-names>R.W.</given-names></name></person-group><article-title>Glucose-induced downregulation of angiotensin II and arginine vasopressin receptors in cultured rat aortic vascular smooth muscle cells. Role of protein kinase C</article-title><source>J. Clin. Invest.</source><year>1992</year><volume>90</volume><fpage>1992</fpage><lpage>1999</lpage><pub-id pub-id-type="doi">10.1172/JCI116079</pub-id><pub-id pub-id-type="pmid">1430222</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G.X.</given-names></name><name><surname>Xu</surname><given-names>Y.Y.</given-names></name><name><surname>Fan</surname><given-names>Y.P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X.L.</given-names></name><name><surname>Zhang</surname><given-names>Y.D.</given-names></name><name><surname>Wu</surname><given-names>J.H.</given-names></name></person-group><article-title>A maladaptive role for EP<sub>4</sub> receptors in mouse mesangial cells</article-title><source>Plos One</source><year>2014</year><volume>9</volume><fpage>e104091</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0104091</pub-id><pub-id pub-id-type="pmid">25122504</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiarelli</surname><given-names>F.</given-names></name><name><surname>Gaspari</surname><given-names>S.</given-names></name><name><surname>Marcovecchio</surname><given-names>M.L.</given-names></name></person-group><article-title>Role of growth factors in diabetic kidney disease</article-title><source>Horm. Metab. Res.</source><year>2009</year><volume>41</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1055/s-0029-1220752</pub-id><pub-id pub-id-type="pmid">19452424</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konya</surname><given-names>V.</given-names></name><name><surname>Marsche</surname><given-names>G.</given-names></name><name><surname>Schuliqoi</surname><given-names>R.</given-names></name><name><surname>Heinemann</surname><given-names>A.</given-names></name></person-group><article-title>E-type prostanoid receptor 4 (EP<sub>4</sub>) in disease and therapy</article-title><source>Pharmacol. Ther.</source><year>2013</year><volume>138</volume><fpage>485</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.03.006</pub-id><pub-id pub-id-type="pmid">23523686</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Satlin</surname><given-names>L.M.</given-names></name><name><surname>Rohatqi</surname><given-names>R.</given-names></name></person-group><article-title>Flow-induced prostaglandin E2 release regulates Na and K transport in the collecting duct</article-title><source>Am. J. Physiol. Renal. Physiol.</source><year>2012</year><volume>303</volume><fpage>632</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00169.2012</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>H.</given-names></name><name><surname>Tanaka</surname><given-names>I.</given-names></name><name><surname>Mukoyama</surname><given-names>M.</given-names></name><name><surname>Sugawara</surname><given-names>A.</given-names></name><name><surname>Mori</surname><given-names>K.</given-names></name><name><surname>Muro</surname><given-names>S.</given-names></name><name><surname>Suganami</surname><given-names>T.</given-names></name><name><surname>Yahata</surname><given-names>K.</given-names></name><name><surname>Ishibashi</surname><given-names>R.</given-names></name><name><surname>Ohuchida</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP<sub>1</sub>-selective antagonist</article-title><source>J. Am. Soc. Nephrol.</source><year>2002</year><volume>13</volume><fpage>1757</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000019782.37851.BF</pub-id><pub-id pub-id-type="pmid">12089371</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>S.A.</given-names><suffix>Jr</suffix></name><name><surname>Palamakumbura</surname><given-names>A.H.</given-names></name><name><surname>Stan</surname><given-names>M.</given-names></name><name><surname>Trackman</surname><given-names>P.C.</given-names></name></person-group><article-title>Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between cAMP and MAPK signaling pathways, and prostaglandin E2-EP<sub>3</sub> receptor mediated activation of the c-JUN N-terminal kinase</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>15416</fpage><lpage>15429</lpage><pub-id pub-id-type="doi">10.1074/jbc.M610432200</pub-id><pub-id pub-id-type="pmid">17428796</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Cellular and molecular mechanisms of renal fibrosis</article-title><source>Nat. Rev. Nephrol.</source><year>2011</year><volume>7</volume><fpage>684</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2011.149</pub-id><pub-id pub-id-type="pmid">22009250</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Sanchez</surname><given-names>O.</given-names></name><name><surname>Lopez-Hernandez</surname><given-names>F.J.</given-names></name><name><surname>Lopez-Novoa</surname><given-names>J.M.</given-names></name></person-group><article-title>An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease</article-title><source>Kidney Int.</source><year>2010</year><volume>77</volume><fpage>950</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1038/ki.2010.88</pub-id><pub-id pub-id-type="pmid">20336053</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyajima</surname><given-names>A.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Asano</surname><given-names>T.</given-names></name><name><surname>Seta</surname><given-names>K.</given-names></name><name><surname>Ueda</surname><given-names>A.</given-names></name><name><surname>Hayakawa</surname><given-names>M.</given-names></name></person-group><article-title>Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction?</article-title><source>J. Urol.</source><year>2001</year><volume>166</volume><fpage>1124</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)65933-2</pub-id><pub-id pub-id-type="pmid">11490310</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention</article-title><source>J. Am. Soc. Nephrol.</source><year>2004</year><volume>15</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000106015.29070.E7</pub-id><pub-id pub-id-type="pmid">14694152</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starostina</surname><given-names>N.G.</given-names></name><name><surname>Kipreos</surname><given-names>E.T.</given-names></name></person-group><article-title>Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors</article-title><source>Trends Cell Biol.</source><year>2012</year><volume>2</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2011.10.004</pub-id><pub-id pub-id-type="pmid">22154077</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons Kovacs</surname><given-names>L.A.</given-names></name><name><surname>Mayhew</surname><given-names>M.B.</given-names></name><name><surname>Orlando</surname><given-names>D.A.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Reed</surname><given-names>S.I.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name><name><surname>Haase</surname><given-names>S.B.</given-names></name></person-group><article-title>Cyclin-dependent kinases are regulators and effectors of oscillations driven by a transcription factor network</article-title><source>Mol. Cell</source><year>2012</year><volume>45</volume><fpage>669</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.12.033</pub-id><pub-id pub-id-type="pmid">22306294</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>J.Y.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name><name><surname>Polyak</surname><given-names>K.</given-names></name><name><surname>Massagu&#x000e9;</surname><given-names>J.</given-names></name><name><surname>Sherr</surname><given-names>C.J.</given-names></name></person-group><article-title>Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation</article-title><source>Cell</source><year>1994</year><volume>79</volume><fpage>487</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90257-7</pub-id><pub-id pub-id-type="pmid">7954814</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Warner</surname><given-names>G.M.</given-names></name><name><surname>Yin</surname><given-names>P.</given-names></name></person-group><article-title>Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model</article-title><source>Am. J. Physiol. Renal. Physiol.</source><year>2013</year><volume>304</volume><fpage>938</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00706.2012</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>H.T.</given-names></name></person-group><article-title>MAPK signal pathways in the regulation of cell proliferation in mammalian cells</article-title><source>Cell Res.</source><year>2002</year><volume>12</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/sj.cr.7290105</pub-id><pub-id pub-id-type="pmid">11942415</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Lee</surname><given-names>H.G.</given-names></name><name><surname>Raina</surname><given-names>A.K.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name><name><surname>Smith</surname><given-names>M.A.</given-names></name></person-group><article-title>The role of mitogen-activated protein kinase pathways in Alzheimer's disease</article-title><source>Neurosignals</source><year>2002</year><volume>11</volume><fpage>270</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1159/000067426</pub-id><pub-id pub-id-type="pmid">12566928</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fassett</surname><given-names>J.</given-names></name><name><surname>Tobolt</surname><given-names>D.</given-names></name><name><surname>Hansen</surname><given-names>L.K.</given-names></name></person-group><article-title>Type I collagen structure regulates cell morphology and EGF signaling in primary rat hepatocytes through cAMP-dependent protein kinase A</article-title><source>Mol. Biol. Cell</source><year>2006</year><volume>17</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1091/mbc.E05-09-0871</pub-id><pub-id pub-id-type="pmid">16251347</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Bu</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>A.D.</given-names></name><name><surname>Holmberg</surname><given-names>L.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>C.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name></person-group><article-title>Sulfur dioxide inhibits vascular smooth muscle cell proliferation via suppressing the Erk/MAP kinase pathway mediated by cAMP/PKA signaling</article-title><source>Cell Death Dis.</source><year>2014</year><volume>5</volume><fpage>e1251</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.229</pub-id><pub-id pub-id-type="pmid">24853429</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Diaz Encarnacion</surname><given-names>M.M.</given-names></name><name><surname>Warner</surname><given-names>G.M.</given-names></name><name><surname>Gray</surname><given-names>C.E.</given-names></name><name><surname>Nath</surname><given-names>K.A.</given-names></name><name><surname>Grande</surname><given-names>J.P.</given-names></name></person-group><article-title>TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process</article-title><source>Am. J. Physiol. Cell Physiol.</source><year>2005</year><volume>289</volume><fpage>C959</fpage><lpage>C970</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00153.2005</pub-id><pub-id pub-id-type="pmid">15930146</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagamatsu</surname><given-names>T.</given-names></name><name><surname>Imai</surname><given-names>H.</given-names></name><name><surname>Yokoi</surname><given-names>M.</given-names></name><name><surname>Nishiyama</surname><given-names>T.</given-names></name><name><surname>Hirasawa</surname><given-names>Y.</given-names></name><name><surname>Nagao</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name></person-group><article-title>Protective Effect of Prostaglandin EP<sub>4</sub>-Receptor Agonist on Anti-glomerular basement membrane antibody-associated nephritis</article-title><source>J. Pharmacol. Sci.</source><year>2006</year><volume>102</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1254/jphs.FP0060401</pub-id><pub-id pub-id-type="pmid">17031072</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahner</surname><given-names>G.</given-names></name><name><surname>Schaper</surname><given-names>M.</given-names></name><name><surname>Panzer</surname><given-names>U.</given-names></name><name><surname>Kluger</surname><given-names>M.</given-names></name><name><surname>Stahl</surname><given-names>R.A.</given-names></name><name><surname>Thaiss</surname><given-names>F.</given-names></name><name><surname>Schneider</surname><given-names>A.</given-names></name></person-group><article-title>Prostaglandin EP<sub>2</sub> and EP<sub>4</sub> receptors modulate expression of the chemokine CCL2 (MCP-1) in response to LPS-induced renal glomerular inflammation</article-title><source>Biochem. J.</source><year>2009</year><volume>422</volume><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1042/BJ20090420</pub-id><pub-id pub-id-type="pmid">19570035</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>R.</given-names></name><name><surname>Jayakumar</surname><given-names>C.</given-names></name><name><surname>Ramesh</surname><given-names>G.</given-names></name></person-group><article-title>Chronic administration of EP<sub>4</sub>-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6</article-title><source>Lab. Invest.</source><year>2013</year><volume>93</volume><fpage>933</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2013.85</pub-id><pub-id pub-id-type="pmid">23817085</pub-id></element-citation></ref></ref-list></back></article>